Jennifer Rosendin is a Director at Intensity with expertise in valuation of intellectual property, economic and financial modeling, and statistical analyses. Ms. Rosendin applies her expertise in conducting rigorous analyses to high-stakes commercial litigation and to assisting clients in evaluating complex business decisions. Ms. Rosendin performs analyses that include the following:
- Reasonable royalties
- Lost profits
- Unjust enrichment
- Commercial success
- Irreparable harm
- Labor and employment
- Business analytics
Examples of Ms. Rosendin’s work include the following projects:
| Patent damages for non-invasive prenatal testing (NIPT). Analyzed lost profits and reasonable royalty damages for alleged infringement of patented NIPT technology, including consideration of the technology, product sales, revenue apportionment, license and supply agreements, and non-infringing alternatives.
| Evaluation of irreparable harm in the context of a preliminary injunction against a medical device. Analyzed sales and market data to determine quantification of potential damages, including issues of nexus, market share loss, price erosion, and reputational effects. Also considered impact of device on the public interest and balance of harms.
| Valuation of telecommunications technology used in correctional facilities. Evaluated lost profits and reasonable royalty damages for patents associated with a specialized telecommunications platform used in correctional facilities. Analyzed economic issues such as the economic contribution of the technology, economic substitutes for the technology, and bargaining in the context of a hypothetical negotiation.
| Evaluation of a potential at-risk drug launch for generic pharmaceutical company. Forecasted potential lost profits and reasonable royalty damages that could result from launching generic drugs at-risk. Developed parameterized model to estimate potential damages under various scenarios, including varying degrees of generic competition and price erosion, launch timing, and the presence of an authorized generic.
| Evaluation of the commercial success of patented technology pertaining to pharmaceutical products for patients with ocular hypertension or glaucoma. Conducted evaluation of commercial success, including analysis of relevant markets, market shares, economic profitability, nexus between the patented technology and product sales, promotional expenditures, and price discounting.
Prior to joining Intensity, Ms. Rosendin served as an economist at a large global professional services corporation focused on infrastructure and development. In this capacity, her work focused on measuring the economic effects of U.S.-funded road, water, and electricity projects in Afghanistan, Iraq, and South Sudan.
Ms. Rosendin earned her M.A. in Development Economics from the University of California, San Diego, and her B.A. in International Relations from the University of California, Berkeley.